ESTRO 2024 - Abstract Book

S1792

Clinical - Lung

ESTRO 2024

Results:

A total of 135 highly relevant radiomic features of the lung and GTV were selected for cluster analysis. The radiomics efficacy prediction analysis suggests that the imaging characteristics of the lung and target area can improve the prediction of short-term efficacy and survival. The areas under the receiver operating characteristic curve (AUC) of DCR, ORR, and OS in the validation set are 0.85 (95%) respectively. CI 0.82-0.87), 0.86 (95%CI 0.83-0.87), 0.70 (95%CI 0.69-0.73).

Conclusion:

When patients receive immunotherapy, lung and target area CT imaging features show strong predictive value for PFS and OS, and are worthy of future prospective evaluation.

Keywords: NSCLC, Efficacy, Radiomics

2936

Digital Poster

SABR for ES- NSCLC in very elderly (≥80 years old) patients: results on 18 years of experience

Marzia Cerrato, Fabio Menegatti, Serena Badellino, Erica Maria Cuffini, Bruna Lo Zito, Ilaria Bonavero, Silvia Leardi, Chiara Casale, Ramona Parise, Giorgia Novero, Mario Levis, Umberto Ricardi

University of Turin, Department of Oncology, Turin, Italy

Purpose/Objective:

Stereotactic ablative radiotherapy (SABR) for early-stage non-small-cell lung cancer (ES-NSCLC) is a valid alternative to surgery in medically inoperable patients. SABR is a non-invasive treatment with limited impact on the quality of life, representing often the unique suitable therapeutic strategy for elderly patients who are frequently already burdened by comorbidities. We report our institutional experience using SABR in the definitive management of ES NSCLC in patients ≥80 years old, analysing the main oncological outcomes and clinical -radiation induced toxicity.

Material/Methods:

This retrospective study included patients ≥ 80 years old, with ECOG PS ≤ 2 affected by T1 -2N0M0 NSCLC treated with SABR between 2003 and 2021 at our Institution. Surgery was contraindicated after multidisciplinary assessment, or refused by patients. Histopathological confirmation of NSCLC was not mandatory. Details on pre existing cardiovascular risk factors, lung comorbidities and lung function tests were collected at baseline. Follow-up visits were scheduled every 3 months for the first 2 years to gather data on acute and delayed toxicity and clinical